introduction helicobacter pylorus pylorus main cause chronic gastritis well one main etiopathogenetic factor development peptic ulcer disease bacterium classified class definite carcinogen world health organization main risk factor etiopathogenesis gastric adenocarcinoma mucosa-associated lymphoid tissue lymphoma despite fact prevalence pylorus declining especially younger population estimated around world population still infected bacterium based wide systematic review meta-analysis prevalence pylorus western europe significantly higher eastern southern european country prevalence pylorus related cohort effect meaning higher among cohort earlier date birth i.e. older cohort higher prevalence pylorus vast majority people acquire bacterium early childhood year age possibility later infection rather low treatment pylorus reinfection rate also low however might higher area low socioeconomic status high prevalence pylorus epidemiological study reported world population shifting towards older adult year old number person aged year expected double upcoming year reported prevalence pylorus older population significantly higher compared younger people resulting higher incidence gastric cancer peptic ulcer disease pylorus -associated condition population even though clear lack epidemiological research older patient available study reported prevalence pylorus ranging subject older adult also associated age-related peculiarity higher number comorbidities concurrent medication lower treatment compliance impaired renal function change drug metabolism well physiological change currently updated maastricht vi/florence well previous maastricht v/florence consensus report management pylorus infection decided separate recommended treatment regimen different age group reported regimen equally effective older younger patient fact limited available study reported standard triple therapy achieved close optimal seldom case optimal effectiveness quadruple therapy sequential therapy reported achieve optimal eradication rate older-aged group described pylorus eradication prescription safe effective older adult although experience quite confined scarcity data regarding pylorus diagnostics treatment older patient also comparing result younger subject latter could evaluate depth population characteristic potentially help therapeutical tailoring different age group fact performing literature search could retrieve european study recent year compared diagnostics treatment pylorus older younger population hand known pylorus resistance rate antibiotic increasing worldwide extensive analysis reported primary clarithromycin resistance european country doubled last year likely older adult might pattern higher antimicrobial resistance due lifelong exposure various antibiotic however population based study china revealed failure rate clarithromycin containing triple therapy especially high younger population whereas higher cure rate observed older subject aim study therefore evaluate compare diagnostic method treatment prescription pylorus infection well effectiveness frequent first- second-line pylorus eradication regimen older younger adult europe method european registry pylorus management hp-eureg hp-eureg international multicentre prospective non-interventional registry recording information management pylorus infection since year hp-eureg protocol establishes national coordinator selected country gastroenterologist recruited study centre provide input registry participant study group study data obtained centre participating country participant patient included hp-eureg since year january patient adult diagnosed pylorus infection study participant divided two group based age younger 18–59 year old older year old age cut-off value group selected based older adult definition source united nation data collection data collected electronic case report form e-crf collecting patient demographic information previous eradication attempt treatment employed well outcome treatment recording detail compliance cure rate follow-up etc adverse event aes information registered redcap database managed hosted asociación española gastroenterología aeg http non-profit scientific medical society focus gastroenterology research data management data quality reviewed evaluating whether study selection criterion met whether information correctly registered ultimately ensure study conducted according highest scientific ethical standard accordance latest revision ethical guideline firstly announced declaration helsinki data discordance resolved querying investigator group emailing variable categorization definition ppi dos categorized according potency acid inhibition low-dose 4.5–27 omeprazole equivalent given twice day standard-dose 32–40 omeprazole equivalent given twice day high-dose 54–128 omeprazole equivalent given twice day likewise duration treatment categorized day ease interpretation sub-analyses performed according treatment duration ppi dos comparing age group younger older subject following category used frequently prescribed first-line treatment triple-ca/m clarithromycin amoxicillin/metronidazole seq cat-cam clarithromycin amoxicillin tinidazole—clarithromycin amoxicillin metronidazole quad-cat-cam quad-pylera three-in-one single-capsule containing metronidazole tetracycline bismuth quad bismuth quad-cab clarithromycin amoxicillin bismuth likewise following category used frequent second-line treatment quad pylera quad quad-lab levofloxacin amoxicillin bismuth triple-al amoxicillin levofloxacin conco-seq concomitant-sequential order calculate effectiveness different pylorus eradication regimen per-protocol intention treat itt modified intention-to-treat mitt analysis used itt analysis includes case registered hp-eureg allowing least 6-month follow-up lost follow-up case considered treatment failure analysis includes case completed follow-up i.e. undertaken valid confirmatory test eradication treatment taken least treatment drug defined protocol mitt designed reach closest result obtained clinical practice therefore included case completed follow-up regardless compliance treatment patient empirically treated without prescribing susceptibility-guided antibiotic treatment included effectiveness analysis aes compliance evaluated patient questioning open-ended question predefined questionnaire face-to-face interview compliance defined physician questioning taken least prescribed drug aes classified depending intensity symptom evaluated corresponding physician mild interfering daily routine moderate affecting daily routine intense/severe allowing normal daily routine serious causing death hospitalization disability congenital anomaly and/or requiring intervention prevent permanent damage statistical analysis continuous variable summarized mean standard deviation qualitative variable presented absolute relative frequency displayed percentage together applicable selected level statistical significance 0.05 two-tailed treatment accounted descriptive univariate analysis purpose multivariate analysis logistic regression performed first controlling frequently prescribed first-line treatment frequently second-line treatment used backward modelling strategy compared model using log-likelihood ratio mitt population dependent variable used evaluate association treatment eradication rate following independent variable age ref 18–59 year old group sex ref female indication ref dyspepsia compliance ref drug intake ppi dose ref low dose treatment length ref day prescribed eradication regimen first line-treatment ref triple-ca/m second-line treatment ref quad pylera quad defined earlier multivariate analysis effect evaluated calculating odds ratio corresponding confidence interval ethic approval statement study approved ethic committee princesa university hospital madrid spain registered clinicaltrials.gov nct02328131 result baseline characteristic figure depicts flow-chart study main result difference demographic diagnostics treatment pylorus infection older younger age group presented table figure study flow chart per-protocol mitt modified intention-to-treat full size image table demographic diagnostics treatment prescription pylorus management older younger european population full size table since year data 49,461 case included hp-eureg used current analysis already mentioned patient divided two group based age 14,467 older aged year older 34,994 younger 18–59 year old patient female older group female younger group 0.05 age group older adult group reported significantly higher intake concurrent medication main evaluated drug group ppis acetylsalicylic acid non-steroidal anti-inflammatory drug statin compared younger subject vs. respectively 0.05 older-aged group characterized statistically significantly higher rate allergy penicillin older compared younger group 0.05 whereas difference evaluated drug group macrolides 0.3 group fluoroquinolones 0.2 vs. 0.1 respectively 0.05 pylorus eradication dyspeptic symptom frequently reported older subject compared younger one vs. respectively 0.05 whereas difference prevalence heartburn group 0.05 main indication treatment pylorus infection older younger age group dyspeptic syndrome vs. respectively peptic ulcer disease vs. respectively 0.05 cause instance gastroesophageal reflux disease erosive gastritis etc accounted indication older younger patient group 0.05 main pylorus diagnostic test used older younger subject treatment histological examination respectively 0.05 rapid urease test rut group 0.05 urea breath test ubt respectively 0.05 microbiological culture respectively 0.05 serology vs. respectively 0.05 main diagnostic test post-treatment group ubt respectively 0.05 stool antigen test respectively 0.05 histological examination respectively 0.05 rut group 0.05 prescription treatment duration ppis age group case treatment-naive first-line treatment quadruple therapy prescribed older younger subject 0.05 triple therapy respectively 0.05 second-line treatment quadruple therapy prescribed older younger age case 0.05 triple therapy respectively 0.05 overall duration first-line treatment older younger adult day case respectively day respectively day respectively 0.05 group overall duration second-line treatment follows day day day case age group 0.05 first-line treatment low ppi dos frequently prescribed group significant difference prescribed ppi dos found group second-line treatment low dos ppis frequently prescribed older adult respectively 0.05 high dos ppis frequently younger adult respectively 0.05 treatment effectiveness detailed analysis widely used first- second-line prescription older younger age group effectiveness itt mitt comparison presented table graphic comparison mitt effectiveness six frequently prescribed first- second-line treatment age group illustrated fig respectively table first- second-line pylorus treatment effectiveness younger older european population full size table figure comparison mitt effectiveness frequent first-line prescription younger older adult full size image figure comparison mitt effectiveness six frequent second-line prescription younger older adult full size image overall first-line treatment effectiveness 89–90 88–89 mitt younger 88–89 89–91 mitt older group effectiveness frequently prescribed first-line regimen standard triple therapy ppi mitt older group whereas mitt younger group 0.05 comparing mitt effectiveness meaning reached suboptimal efficacy rate either group remaining triple therapy failed reach optimal eradication rate well optimal eradication rate first-line treatment achieved using quadruple therapy quadruple ppi quadruple ppi single-capsule bismuth quadruple therapy frequently used sequential therapy ppi age group statistically significant difference eradication effectiveness age group reported standard triple therapy ppi quadruple ppi sequential ppi therapy used overall second-line treatment effectiveness mitt younger older subject efficacy popular second-line prescription ppi mitt older adult group whereas mitt younger adult group 0.05 analysis meaning also achieved suboptimal eradication rate optimal eradication rate younger group achieved using triple ppi moxifloxacin quadruple ppi therapy older group single-capsule bismuth quadruple therapy managed reach optimal treatment effectiveness statistically significant difference age group second-line treatment effectiveness reported quadruple ppi therapy used multivariate analysis detailed multivariate analysis first- second-line treatment presented table performing multivariate analysis calculated compliance treatment quadruple bismuth-based prescription including single-capsule bismuth quadruple therapy longer treatment duration day vs. day day vs. day higher acid inhibition high ppis dos vs. low medium ppis dos vs. low sequential cat/cam quadruple cat/cam quadruple cab prescription well belonging older adult group main factor associated higher mitt cure rate first-line treatment table independent variable associated higher mitt rate first- second-line treatment full size table second-line treatment main factor associated higher mitt rate longer treatment duration day vs. day day treatment vs. day good treatment compliance higher ppis dos high ppis dos vs. low medium ppis dos vs. low compared quadruple bismuth-based prescription including single-capsule bismuth quadruple therapy triple-al conco-seq prescription associated significantly lower mitt rate compliance safety treatment compliance group overall aes rate lower older subject compared younger adult 24–26 vs. 22–24 respectively 0.05 however severe aes frequent older patient frequent aes older younger subject dysgeusia group nausea respectively diarrhea respectively vomiting respectively aes mild moderate intensity lasted 7–14 day frequent severe aes among older younger age group asthenia respectively 0.05 anorexia respectively 0,05 abdominal pain respectively 0.05 among older adult 1.5 stop taking medication due aes whereas 1.2 younger group 0.05 discussion study evaluated difference pylorus diagnostics treatment older younger european population would like point analysis one available evaluating older-aged population comparing younger subject additionally one study providing data large number patient europe enabling accurate data reliable statistical result analysis confirmed expected epidemiological hypothesis regarding baseline characteristics—compared younger patient older subject taking concurrent medication reported higher rate allergy penicillin even though higher number concurrent medication higher rate drug allergy usually associated worse treatment compliance confirmed study influence efficacy eradication therapy diagnostics pylorus also complied current guideline study confirmed invasive diagnostic method histology rut frequent initial diagnosis pylorus prior treatment anticipated method also common older population confirmation eradication ubt preferred choice followed sat age group performed study revealed quadruple therapy superior triple therapy regarding effectiveness fact study demonstrated quadruple therapy frequently prescribed first- second-line treatment age group frequent treatment duration 10–14 day age group line current guideline seven day duration treatment longer recommended even though case day treatment duration age group case registered early year registry reported previous hp-eureg research also accordance maastricht v/florence consensus report updated year day treatment duration longer recommended could expected dos ppi might lower older population due higher chance possible aes e.g. diarrhea clostridioides difficile infection however find significant difference age group regarding ppi dose first line therapy difference second-line clinically relevant multivariate analysis revealed high dos ppis associated better mitt rate first- second-line therapy however low dos ppis prescribed frequently first-line treatment age group could speculate prescribing gastroenterologist acquainted guideline cautious possible aes especially older patient hand also point clear shift low dos ppis high dos ppis throughout duration hp-eureg low dos ppis predominant beginning registry year however since year release updated maastricht v/florence consensus report rate higher ppis dos started increasing predominantly represented high-dose ppis—almost half hp-eureg case concerning pylorus eradication regimen state use main first second-line prescription older younger european population met recommendation maastricht v/florence consensus report however frequently prescribed first-line therapy age group spite many country clarithromycin resistance rate standard triple therapy ppi levofloxacin containing triple therapy frequently used rescue regimen age group previously recommended one main goal research evaluate effectiveness main first- second-line pylorus eradication regimen older younger age group found overall first-line treatment effectiveness close optimal eradication rate younger subject mitt whereas optimal close optimal mitt older one effectiveness popular first-line prescription standard triple therapy ppi suboptimal age group triple therapy ppi ppi show even worse effectiveness optimal eradication rate achieved using bismuth non-bismuth-based quadruple therapy ppi ppi single-capsule bismuth quadruple therapy pylera® popular sequential therapy ppi age group optimal effectiveness treatment regimen also confirmed published study statistically significant difference effectiveness age group reported standard triple therapy ppi quadruple ppi sequential ppi therapy used difference remaining analysed prescription respect worthwhile mentioning even though statistically significant difference age group various parameter including effectiveness different prescription difference might clinically non-significant interpreted caution ranged 1–2 could due merely large sample size therefore case considered difference clinically irrelevant even though statistically significant overall effectiveness second-line treatment suboptimal mitt age group effectiveness main second-line regimen ppi suboptimal age group fact regimen achieved optimal eradication rate older age group single-capsule bismuth quadruple therapy pylera younger group optimal eradication rate achieved using triple ppi quadruple ppi prescription fact statistically significant difference second-line treatment effectiveness older younger adult obtained previously mentioned bismuth quadruple ppi prescription vs. mitt respectively multivariate analysis revealed expected result non-bismuth especially bismuth-based quadruple therapy frequent ppi single capsule pylera® ppi associated better mitt cure rate first-line treatment effectiveness analysis revealed bismuth-containing regimen achieved optimal close-to-optimal eradication rate also confirmed study current guideline shifting towards bismuth-based quadruple therapy main pylorus treatment regimen recommendation given clarithromycin resistance rate increasing worldwide another possible issue albeit confirmed study possibility worse treatment compliance older subject even though older-aged population associated higher number concurrent medication treatment compliance satisfactory age group reaching interestingly older adult experienced statistically significantly aes compared younger group however consider whether difference really clinically relevant may due previously stated large number subject age group nonetheless age group presented similar safety profile older younger adult without aes whereas severe aes slightly frequent older-aged subject compare study result available similar study japanese study year also compared diagnostics efficacy safety pylorus eradication age group younger year old 65–74 year super-old year study reported similar indication chronic gastritis pud eradication however aes rate old super-old group significantly lower compared study compared analysis study also reported better effectiveness main standard triple therapy ppi achieved optimal overall eradication rate comparing age group super-old patient significantly frequent indication chronic gastritis frequent indication pud compared group japanese study pylorus eradication rate older patient reported lower compared younger patient remarkable difference seen among group efficacy prescribed regimen significant difference observed comparison rate among group another small chinese study also analysed efficacy pylorus eradication age group using bismuth-based quadruple therapy day yield significant difference either itt analysis age group study also reported excellent eradication rate age group one main weakness study possible heterogeneity data hp-eureg currently includes european country various region might different approach management pylorus infection could affected diverse factor availability local antimicrobial resistance rate financial capability availability diagnostic method local antibiotic market well knowledge objectivity gastroenterologist study included large european cohort providing accurate pan-european data case previously published available study hp-eureg different european country despite aforementioned concern acknowledged multicentre collaboration gathering information daily routine gastroenterological practice one best way secure critical mass knowledge encompassing inclusion even difficult-to-treat case well offering power statistical analysis conclusion general approach diagnostics treatment pylorus infection differ older younger european population main difference reported concurrent medication allergy penicillin aes type prescribed regimen triple vs. quadruple first- second-line treatment generally well-tolerated age group effectiveness frequent first- second-line triple therapy younger older population suboptimal optimal effectiveness rate mostly achieved using bismuth non-bismuth-based quadruple therapy quadruple ppi quadruple ppi quadruple ppi single capsule bismuth quadruple pylera® sequential first line first-line treatment quadruple ppi younger adult single capsule bismuth pylera® second-line treatment although statistically significant clinically relevant difference effectiveness older younger patient observed frequently prescribed first- second-line prescription